Stockreport

Viridian Therapeutics (VRDN) Is Up 15.9% After $300 Million Royalty Deal to Fund Thyroid Eye Drug – Has The Bull Case Changed? [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF unlocking up to US$300 million to support the commercial launch and development of veligrotug and VRDN-003 for thyroid eye disease. This deal provides Viridian with si [Read more]